Hospira Receives FDA Approval for Azithromycin for Injection
Posted on: Monday, 29 June 2009, 10:41 CDT
ADD-Vantage is a specially-designed, two-part system that does not require clinicians to use a needle and syringe to mix the drug and the solution. This reduces the risk of accidental needlesticks, enhances workflow and can result in less waste due to stability and shelf-life factors.
"Hospira is the first company to offer azithromycin in an advanced drug delivery system," said
Hospira's specialty injectable pharmaceuticals (SIP) offering includes approximately 200 generic injectable drugs in many dosages and formulations. In addition, many of its products are available in popular differentiated formats, several of which are proprietary, such as its ADD-Vantage System and iSecure(R) prefilled syringes. Therapeutic areas include anesthesia, anti-infectives, analgesics, cardiovascular, oncology, emergency and other areas. Hospira has approximately 25 generic drugs scheduled to launch in various regions around the world in 2009 and 2010.
About Hospira
Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in
SOURCE Hospira, Inc.
Source: PR Newswire
Related Articles
- Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
- Pharmaceutical Supply System Activates Rx Response for Second Time in 10 Days to Address Potential Impact From Hurricane Ike
- Pharmaceutical Supply System Activates Rx Response to Provide Single Point of Contact for Resolution of Pharmaceutical Supply Obstacles Associated With Hurricane Gustav
- MTM Study Reports Improved Quality and Economic Outcomes Using Medication Management Systems' Assurance Pharmaceutical Care System(TM)
- California Biotechnology Company Takes Aim at Pancreatic Cancer With an Advanced Phase I/II Clinical Trial Using Rexin-G(TM), a Targeted Injectable Gene Delivery System
- Hemispherx and Armada Health Care Enter Agreement to Launch Alferon N Injection(R) Via Specialty Pharmacy Network
- Specialty Biotech Drug Spending Skyrockets
- Generics Will Benefit As 75 Drugs Lose Their Patent Protections
- American Pharmaceutical Partners Receives FDA Approval for Azithromycin for Injection
- Phase 2 Study Shows Lilly/Alkermes Inhaled Insulin System Achieved Blood Sugar Levels Similar to Injected Insulin; 80 Percent of Diabetes Patients in Study Preferred Inhaled Insulin System to Mealtime Injections
 |
 |
User Comments (0)
RSS Feeds